AF
PBYI icon

Amalgamated Financial’s Puma Biotechnology PBYI Stock Holding History

Amalgamated Financial’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$15K Buy
+5,256
New +$13.6K ﹤0.01% 2821

Other funds holding PBYI

CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Amalgamated Financial's PBYI Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Puma Biotechnology (PBYI) in Q1 2022: 5,256 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #2821 among its holdings.

104 funds tracked by Wall St. Rank hold PBYI as of Q1 2022.

  • Amalgamated Financial held 5,256 shares of Puma Biotechnology worth $15K as of Q1 2022.
  • Puma Biotechnology was a new Amalgamated Financial position in Q1 2022.
  • Puma Biotechnology made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2821 holding.
  • 104 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.